184 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
the Australian R&D tax incentive program as a result of recent Australian Taxation Office guidance.
The decrease in R&D compensation expense … and accounting fees. The additional increase of $0.4 million was due to a change in estimate related to the Australian R&D tax incentive program
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
the Australian R&D tax incentive program as a result of recent Australian Taxation Office guidance.
The decrease in R&D compensation expense for the year ended … fees. The additional increase of $0.4 million was due to a change in estimate related to the Australian R&D tax incentive program.
The decrease in G
8-K
EX-99.1
p1xdqx 26rj31tf
15 May 23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:10am
8-K
EX-99.1
ywol067exaq 5qj
15 Nov 21
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
9:25am
8-K
EX-99.1
2zxe8sg0
13 Aug 21
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
9:30am
8-K
EX-99.1
y3p n7r4yjd
14 May 21
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
9:15am